MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317121 | Name: Pimavanserin free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pimavanserin, also known as ACP-103, is an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors. Pimavanserin is a novel drug candidate for Parkinson's psychosis.Parkinson's disease psychosis (PDP) is a condition that may develop in up to 60 % of Parkinson's patients, and is a major reason for nursing home placement for those affected.

Chemical Structure

Pimavanserin free base
Pimavanserin free base
CAS#706779-91-1 (free base)

Theoretical Analysis

MedKoo Cat#: 317121

Name: Pimavanserin free base

CAS#: 706779-91-1 (free base)

Chemical Formula: C25H34FN3O2

Exact Mass: 427.2635

Molecular Weight: 427.56

Elemental Analysis: C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
200mg USD 425.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,050.00 2 Weeks
2g USD 1,850.00 2 Weeks
5g USD 3,050.00 2 Weeks
10g USD 4,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
706779-91-1 (free base) 706782-28-7 (tartrate)
Synonym
ACP-103; ACP 103; ACP103; Pimavanserin; trade name: Nuplazid.
IUPAC/Chemical Name
N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
InChi Key
RKEWSXXUOLRFBX-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
SMILES Code
O=C(NCC1=CC=C(OCC(C)C)C=C1)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 706779-91-1 ( Pimavanserin ) 706782-28-7 (Pimavanserin tartrate)
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.
In vitro activity:
Autophagy was induced upon PVT (pimavanserin) treatment in pancreatic ducal adenocarcinoma (PDAC) cells. Interestingly, PVT induced the expression of autophagy markers ULK1, FIP200, Atg101, Beclin-1, Atg5, LC3A/B, and cleavage of caspase-3, an indicator of apoptosis in several PDAC cells. ULK1 agonist LYN-1604 enhanced the autophagic and apoptotic effects of PVT. On the other hand, autophagy inhibitors chloroquine and bafilomycin blocked the autophagic and apoptotic effects of PVT in PDAC cells. Reference: Cancers (Basel). 2021 Nov 12;13(22):5661. https://pubmed.ncbi.nlm.nih.gov/34830816/
In vivo activity:
A potent 5-hydroxytryptamine (5-HT)2A receptor inverse agonist and antagonist, ACP-103 [N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1, active:salt)], was evaluated for its ability to reduce the primary motor symptom of tremor using tacrine-induced tremulous jaw movements in rats, which is an animal model of parkinsonian tremor. Furthermore, ACP-103 was evaluated for its ability to reduce levodopa-induced dyskinesias in monkeys rendered parkinsonian with MPTP [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine]. ACP-103 reduced tacrine-induced tremulous jaw movements in rats. In addition, ACP-103 administered in combination with levodopa caused a dose-related reduction in dyskinesias in monkeys. Reference: Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. https://pubmed.ncbi.nlm.nih.gov/18534670/
Solvent mg/mL mM
Solubility
Ethanol:PBS (pH 7.2) (1:1) 0.5 1.17
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 427.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ramachandran S, Kaushik IS, Srivastava SK. Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment. Cancers (Basel). 2021 Nov 12;13(22):5661. doi: 10.3390/cancers13225661. PMID: 34830816; PMCID: PMC8616166. 2. Liu ZZ, Liu XN, Fan RC, Jia YP, Zhang QK, Gao XQ, Wang YQ, Yang MQ, Ji LZ, Zhou YQ, Li HL, Li P, Tang B. Identification of pimavanserin tartrate as a potent Ca2+-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Acta Pharmacol Sin. 2021 Nov;42(11):1860-1874. doi: 10.1038/s41401-021-00724-2. Epub 2021 Aug 6. PMID: 34363007; PMCID: PMC8563877. 3. Yuede CM, Wallace CE, Davis TA, Gardiner WD, Hettinger JC, Edwards HM, Hendrix RD, Doherty BM, Yuede KM, Burstein ES, Cirrito JR. Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease. J Neurochem. 2021 Mar;156(5):658-673. doi: 10.1111/jnc.15260. Epub 2021 Jan 10. PMID: 33278025; PMCID: PMC7946332. 4. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010. PMID: 18534670; PMCID: PMC2806670.
In vitro protocol:
1. Ramachandran S, Kaushik IS, Srivastava SK. Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment. Cancers (Basel). 2021 Nov 12;13(22):5661. doi: 10.3390/cancers13225661. PMID: 34830816; PMCID: PMC8616166. 2. Liu ZZ, Liu XN, Fan RC, Jia YP, Zhang QK, Gao XQ, Wang YQ, Yang MQ, Ji LZ, Zhou YQ, Li HL, Li P, Tang B. Identification of pimavanserin tartrate as a potent Ca2+-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Acta Pharmacol Sin. 2021 Nov;42(11):1860-1874. doi: 10.1038/s41401-021-00724-2. Epub 2021 Aug 6. PMID: 34363007; PMCID: PMC8563877.
In vivo protocol:
1. Yuede CM, Wallace CE, Davis TA, Gardiner WD, Hettinger JC, Edwards HM, Hendrix RD, Doherty BM, Yuede KM, Burstein ES, Cirrito JR. Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease. J Neurochem. 2021 Mar;156(5):658-673. doi: 10.1111/jnc.15260. Epub 2021 Jan 10. PMID: 33278025; PMCID: PMC7946332. 2. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010. PMID: 18534670; PMCID: PMC2806670.
1: Gou W, Dai P, Wang M, Wang Y, Ma N, Zhou X, Xu Y, Zhang L, Li C. Synthesis of Diverse Ureas from Amines and CO2 at Atmospheric Pressure and Room Temperature. J Org Chem. 2024 Aug 23. doi: 10.1021/acs.joc.4c01474. Epub ahead of print. PMID: 39180140. 2: Ridler K, Rizzo G, Burstein ES, Forsberg Morén A, Stepanov V, Halldin C, Rabiner EA. Imaging the 5-HT2C receptor with PET: Evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain. J Cereb Blood Flow Metab. 2024 Aug 21:271678X241276312. doi: 10.1177/0271678X241276312. Epub ahead of print. PMID: 39169749. 3: Oguma T, Jino K, Nakahara K, Asada H, Fuchino K, Nagatani K, Kouki K, Okamoto R, Takai N, Koda K, Fujita S, Sekiguchi Y, Yasuo K, Mayumi K, Abe A, Imono M, Horiguchi N, Iwata S, Kusakabe KI. Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. J Med Chem. 2024 Aug 22;67(16):14478-14492. doi: 10.1021/acs.jmedchem.4c01244. Epub 2024 Aug 13. PMID: 39137033. 4: Imlay RK, Alsayed M, Starcher M, Tager A, Griffith J. Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis. Cureus. 2024 Jul 11;16(7):e64316. doi: 10.7759/cureus.64316. PMID: 39130906; PMCID: PMC11316412. 5: Stamenović J, Živadinović B, Đurić V. Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review. J Chin Med Assoc. 2024 Aug 9. doi: 10.1097/JCMA.0000000000001146. Epub ahead of print. PMID: 39118220. 6: Gunther M, Jiang S, Maldonado JR. Pimavanserin for Delirium Management in the Setting of Parkinson's Disease: A Case Report. J Acad Consult Liaison Psychiatry. 2024 Jul 26:S2667-2960(24)00075-2. doi: 10.1016/j.jaclp.2024.07.007. Epub ahead of print. PMID: 39069171. 7: Colijn MA. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review. J Neuropsychiatry Clin Neurosci. 2024 Jul 22:0. doi: 10.1176/appi.neuropsych.20230231. Epub ahead of print. PMID: 39034670. 8: Gu J, Qu Y, Shen Y, Zhou Q, Jiang Y, Zhu H. Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database. J Affect Disord. 2024 Oct 1;362:742-748. doi: 10.1016/j.jad.2024.07.103. Epub 2024 Jul 17. PMID: 39029673. 9: Rajagopalan K, Rashid N, Gopal D, Doshi D. Falls and Fractures among Nursing Home Residents Treated with Pimavanserin versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson's Disease Psychosis. Drugs Real World Outcomes. 2024 Jun 24. doi: 10.1007/s40801-024-00433-2. Epub ahead of print. PMID: 38914856. 10: Rajagopalan K, Rashid N, Gopal D, Doshi D. Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J Comp Eff Res. 2024 Jul;13(7):e240038. doi: 10.57264/cer-2024-0038. Epub 2024 Jun 8. PMID: 38850129; PMCID: PMC11225156. 11: Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease. Expert Opin Emerg Drugs. 2024 Jun 11:1-15. doi: 10.1080/14728214.2024.2363215. Epub ahead of print. PMID: 38822731. 12: Yunusa I. Pimavanserin's Safety Profile: Insights from a Phase 3b Clinical Trial. J Alzheimers Dis. 2024;99(4):1217-1220. doi: 10.3233/JAD-240274. PMID: 38788080. 13: Isaacson SH, Pahwa R, Pagan F, Abler V, Truong D. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis. Clin Park Relat Disord. 2024 May 6;10:100256. doi: 10.1016/j.prdoa.2024.100256. PMID: 38770047; PMCID: PMC11103413. 14: Komatsu Y, Takehara M, Hart X, Takahashi Y, Hori S, Ueno F, Uchida H. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments. Pharmacopsychiatry. 2024 May 6. doi: 10.1055/a-2307-6484. Epub ahead of print. PMID: 38710208. 15: Abdul-Rahman T, Herrera-Calderón RE, Aderinto N, Kundu M, Wireko AA, Adebusoye FT, Ekerin O, Lawal L, Mykolaivna NI, Alexiou A, Almashjary MN, Perveen A, Ashraf GM. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine. J Integr Neurosci. 2024 Apr 12;23(4):80. doi: 10.31083/j.jin2304080. PMID: 38682215. 16: Dudzik P, Lustyk K, Pytka K. Beyond dopamine: Novel strategies for schizophrenia treatment. Med Res Rev. 2024 Sep;44(5):2307-2330. doi: 10.1002/med.22042. Epub 2024 Apr 23. PMID: 38653551. 17: Muneta-Arrate I, Miranda-Azpiazu P, Horrillo I, Diez-Alarcia R, Meana JJ. Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain. Br J Pharmacol. 2024 Apr 21. doi: 10.1111/bph.16368. Epub ahead of print. PMID: 38644550. 18: Daeschler D, Fugh-Berman A. Parkinson's Disease Psychosis and the Marketing of Pimavanserin. Int J Soc Determinants Health Health Serv. 2024 Jul;54(3):272-284. doi: 10.1177/27551938241231531. Epub 2024 Apr 9. PMID: 38592164. 19: Pagan FL, Schulz PE, Torres-Yaghi Y, Pontone GM. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis. CNS Drugs. 2024 May;38(5):333-347. doi: 10.1007/s40263-024-01084-1. Epub 2024 Apr 8. PMID: 38587586; PMCID: PMC11026222. 20: Cummings J, Lanctot K, Grossberg G, Ballard C. Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders: A Review. JAMA Neurol. 2024 Jun 1;81(6):645-653. doi: 10.1001/jamaneurol.2024.0586. PMID: 38558015; PMCID: PMC11164642.